Guggenheim downgraded Q32 Bio (QTTB) to Neutral from Buy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QTTB:
- Q32 Bio price target lowered to $20 from $80 at Oppenheimer
- Q32 Bio Announces Mixed Results in Clinical Trials
- Q32 Bio price target lowered to $20 from $85 at Piper Sandler
- Q32 Bio downgraded to Market Perform from Outperform at Leerink
- Q32 Bio downgraded to Outperform from Strong Buy at Raymond James